Botulinum Toxin for Tinnitus: What the Evidence Actually Supports Across Masseter, Temporalis, Peri-Auricular and Migraine Protocols

Tinnitus affects an estimated 10–15% of adults, and no pharmacological agent is recommended for its routine treatment by either the American Academy of Otolaryngology–Head and Neck Surgery clinical practice guideline (2014) or NICE guideline NG155 (2020). Botulinum toxin has been proposed for tinnitus on several distinct rationales — chemodenervation of myoclonic middle ear and palatal muscles, reduction of masticatory nociceptive input in somatosensory tinnitus, and modulation of central sensitisation in patients with comorbid chronic migraine. These rationales are frequently conflated in clinical marketing.

Rich, Famous or Skilled: Three Business Models in Aesthetic Medicine, the Time They Demand, and the Personalities They Reward

Practitioners enter aesthetic medicine from widely divergent starting points — career change, supplementary income, flexibility around caregiving, entrepreneurial ambition, or clinical interest — yet training, marketing and business advice in the sector are delivered as though all entrants share one objective. The result is a systematic mismatch between the practice a clinician builds and the outcome they actually want.

Managing Dermal Filler Complications: A Step-by-Step Protocol Handbook for Prevention, Recognition and Reversal

Dermal fillers are among the most frequently performed non-surgical procedures worldwide, and hyaluronic acid accounts for the majority of injectable soft-tissue augmentation. Most adverse events are mild and self-limiting, but vascular occlusion, tissue necrosis, visual loss and cerebrovascular injury can produce permanent morbidity. Published consensus guidance is now substantial, yet complications continue to be mismanaged at the level of sequence, threshold and technique rather than knowledge.

How to Open a Medical Cannabis Clinic in the UK: Regulation, Set-Up Costs, Pricing Models and the Business Case

Cannabis-based products for medicinal use (CBPMs) have been legally prescribable in the UK since November 2018, yet NHS prescribing remains negligible and essentially all activity has migrated to the private sector. Prohibition Partners estimates the UK medical cannabis market at £302–389 million with more than 140,000 patients in 2026, growth that has attracted clinicians without a comparable body of business-facing literature to guide entry decisions.

How Long Does Botox Last? Axonal Sprouting, SNAP-25 Persistence and Why Duration Is a Nerve-Regeneration Problem

Clinical duration of botulinum neurotoxin is routinely described as the toxin 'wearing off', implying elimination of the active molecule. The underlying biology is different: intracellular light-chain protease activity persists for many months, cleaved SNAP-25 fragments exert a durable dominant-negative effect, and functional recovery is driven by motor nerve terminal sprouting and subsequent remodelling. The 2026 European approval of trenibotulinumtoxinE (serotype E), with onset from eight hours and duration of two to three weeks, has renewed clinical interest in what actually sets duration.

Are Sunbeds Bad for You? Skin Cancer Risk, Tanning Dependence and the Economics of the UK Sunbed Debate

Ultraviolet radiation from sunbeds is classified by the WHO's International Agency for Research on Cancer as carcinogenic to humans (Group 1). In May 2026 the Department of Health and Social Care opened a consultation on strengthening commercial sunbed regulation in England under the Sunbeds (Regulation) Act 2010, and the British Photodermatology Group and British Association of Dermatologists have called for a complete commercial ban. Public debate remains polarised between an absolutist health position and a business-survival position, with little integrated analysis.

The Marketing House Trap: Where Aesthetic Clinic Marketing Budgets Go to Die

The Compounding Clinic: Why Search Visibility, Not Word of Mouth, Builds the Sustainable Aesthetic Practice

The Hard Truth About a Career in Aesthetic Medicine: How AI Has Made the Solo Practice Possible

OnabotulinumtoxinA (Botox) for Migraine Prevention: Why Neurology Uses 31–39 Injection Sites and 155–195 Units

Combining Botulinum Toxin and Corticosteroid Injections for Trigger Point Management

Skin Booster Modalities in Aesthetic Dermatology: Mechanisms, Evidence, Safety, Protocols, and Sequencing

Fibre-Optic Subdermal Diode-Laser Rejuvenation of the Lower Face (Endolift-Type Endolaser)

Botulinum Toxin Type A in Orofacial Pain Management: A Clinical Review

Combining Botulinum Toxin and Corticosteroid Injections for Trigger Point Management

Skin Booster Modalities in Aesthetic Dermatology: Mechanisms, Evidence, Safety, Protocols, and Sequencing